APA (7th ed.) Citation

Yhim, H., Lee, N., Song, E., Yim, C., Jeon, S. Y., Lee, B., . . . Kwak, J. (2016). Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease. Acta Haematologica, 135(3), 133. https://doi.org/10.1159/000440936

Chicago Style (17th ed.) Citation

Yhim, Ho-Young, et al. "Long-Term Outcomes After Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease." Acta Haematologica 135, no. 3 (2016): 133. https://doi.org/10.1159/000440936.

MLA (9th ed.) Citation

Yhim, Ho-Young, et al. "Long-Term Outcomes After Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease." Acta Haematologica, vol. 135, no. 3, 2016, p. 133, https://doi.org/10.1159/000440936.